NRX Pharmaceuticals vs Xenon Pharmaceuticals
NRXP and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NRXP and XENE compare
Xenon Pharmaceuticals is the larger company, worth 35 times as much as NRX Pharmaceuticals ($3.8B against $106M).
Xenon Pharmaceuticals scores higher on the StockData Score (7 against 0 for NRX Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NRXP | XENE |
|---|---|---|
| Size and price | ||
| Market cap | $106M | $3.8B |
| Share price | $2.45 | $38.78 |
| Change, 1 year | −1.6% | −4.9% |
| Change, 5 years | −96.4% | 41.3% |
| Beta (5Y) | 1.15 | 0.26 |
| Employees | 29 | 370 |
| StockData Score | ||
| Total score | 0 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 31.3× | – |
| P/B | – | 3.0× |
| FCF yield | – | −9.0% |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | – | −25.3% |
| Profitability | ||
| Gross margin | 46.6% | – |
| Operating margin | −586% | – |
| Net margin | −692% | – |
| Return on equity | – | −43.6% |
| Return on invested capital | – | −152% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −17.4× | – |
| Current ratio | 0.86 | 21.02 (better) |
| Altman Z-score | −13.45 | 40.35 (better) |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 26.9% | 104% |
| Held by insiders | 15.6% | 0.17% |
| Insider net buying, 12 months | – | −$20.3M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 28.6% | 7.6% |
Go deeper
- NRXP stock overview
- NRXP income statement
- NRXP valuation and score
- XENE stock overview
- XENE income statement
- XENE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.